Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement.
Across FY2007–FY2025: $10.72B in buybacks, $3.99B in dividends.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
2 filings have incomplete source or extraction coverage. Verified observations are shown; missing observations do not establish that debt was unchanged.
Covenants
Some sections could not be verified in 1 agreement document. Other restrictions or tests may apply.
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
5.000% senior notes due 2036
Note · Quest Diagnostics Incorporated
Reference: 5.000% senior notes due 2036
Active
Original principal
USD 500,000,000
Outstanding
—
Commitment
—
Availability
—
Maturity
Jun 30, 2036
Last reported interest terms:
5%
Reported 2026-05-08Later filings may not restate these terms; this does not confirm they still apply.
Covenant terms for this agreement are not yet verified.
On May 6, 2026, Quest Diagnostics Incorporated (the “Company”) issued $500,000,000 aggregate principal amount of 5.000% senior notes due 2036 (the “Notes”).
Issuer evidence: On May 6, 2026, Quest Diagnostics Incorporated (the “Company”) issued $500,000,000 aggregate principal amount of 5.000% senior notes due 2036 (the “Notes”).
Supporting evidence: The Notes will mature on June 30, 2036. The Notes will be the senior unsecured obligations of the Company and will rank equally with the Company’s other existing and future senior unsecured obligations. The Notes will not be entitled to the benefit of any sinking fund.
Supporting evidence: On May 6, 2026, Quest Diagnostics Incorporated (the “Company”) issued $500,000,000 aggregate principal amount of 5.000% senior notes due 2036 (the “Notes”).
Supporting evidence: On May 6, 2026, Quest Diagnostics Incorporated (the “Company”) issued $500,000,000 aggregate principal amount of 5.000% senior notes due 2036 (the “Notes”).
On April 27, 2026, Quest Diagnostics Incorporated (the “Company”) issued a press release announcing the pricing of a public offering of $500 million aggregate principal amount of its 5.000% senior notes due 2036 (the “Notes”) under the Company’s shelf registration statement. The Company intends to use the net proceeds from the offering for general corporate purposes, which may include the repayment of indebtedness. The indebtedness the Company may repay includes its $500 million aggregate principal amount of 3.45% Senior Notes that mature on June 1, 2026. The Company expects to receive the net proceeds upon closing of the offering on May 6, 2026, subject to customary closing conditions. A copy of the press release, dated April 27, 2026, is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference into this Current Report on Form 8-K.
Issuer evidence: On April 27, 2026, Quest Diagnostics Incorporated (the “Company”) issued a press release announcing the pricing of a public offering of $500 million aggregate principal amount of its 5.000% senior notes due 2036 (the “Notes”) under the Company’s shelf registration statement. The Company intends to use the net proceeds from the offering for general corporate purposes, which may include the repayment of indebtedness. The indebtedness the Company may repay includes its $500 million aggregate principal amount of 3.45% Senior Notes that mature on June 1, 2026. The Company expects to receive the net proceeds upon closing of the offering on May 6, 2026, subject to customary closing conditions. A copy of the press release, dated April 27, 2026, is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference into this Current Report on Form 8-K.
Supporting evidence: On April 27, 2026, Quest Diagnostics Incorporated (the “Company”) issued a press release announcing the pricing of a public offering of $500 million aggregate principal amount of its 5.000% senior notes due 2036 (the “Notes”) under the Company’s shelf registration statement. The Company intends to use the net proceeds from the offering for general corporate purposes, which may include the repayment of indebtedness. The indebtedness the Company may repay includes its $500 million aggregate principal amount of 3.45% Senior Notes that mature on June 1, 2026. The Company expects to receive the net proceeds upon closing of the offering on May 6, 2026, subject to customary closing conditions. A copy of the press release, dated April 27, 2026, is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference into this Current Report on Form 8-K.
Supporting evidence: On April 27, 2026, Quest Diagnostics Incorporated (the “Company”) issued a press release announcing the pricing of a public offering of $500 million aggregate principal amount of its 5.000% senior notes due 2036 (the “Notes”) under the Company’s shelf registration statement. The Company intends to use the net proceeds from the offering for general corporate purposes, which may include the repayment of indebtedness. The indebtedness the Company may repay includes its $500 million aggregate principal amount of 3.45% Senior Notes that mature on June 1, 2026. The Company expects to receive the net proceeds upon closing of the offering on May 6, 2026, subject to customary closing conditions. A copy of the press release, dated April 27, 2026, is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference into this Current Report on Form 8-K.
5.000% Senior Notes due 2036
Note · Quest Diagnostics Incorporated
Reference: 5.000% Senior Notes due 2036
Active
Original principal
USD 500,000,000
Outstanding
—
Commitment
—
Availability
—
Maturity
Jun 30, 2036
Last reported interest terms:
5%
Reported 2026-05-08Later filings may not restate these terms; this does not confirm they still apply.
Covenant terms for this agreement are not yet verified.
WHEREAS, the issuance and sale of $500,000,000 aggregate principal amount of a new series of the Company’s 5.000% Senior Notes due 2036 (the “Notes”) pursuant to this Twenty-Fourth Supplemental Indenture have been authorized by resolutions adopted by the Board of Directors of the Company;
Issuer evidence: TWENTY-FOURTH SUPPLEMENTAL INDENTURE (this “Twenty-Fourth Supplemental Indenture”), dated as of May 6, 2026, between QUEST DIAGNOSTICS INCORPORATED, a Delaware corporation (the “Company”), and THE BANK OF NEW YORK MELLON, a New York banking corporation, as Trustee (the “Trustee”).
Supporting evidence: (c) The entire outstanding principal of the Notes shall be payable on June 30, 2036.
Supporting evidence: The rate at which the Notes shall bear interest shall be 5.000% per annum, and the date from which interest shall accrue on the Notes shall be May 6, 2026, or the most recent Interest Payment Date to which interest has been paid or provided for
Supporting evidence: WHEREAS, the issuance and sale of $500,000,000 aggregate principal amount of a new series of the Company’s 5.000% Senior Notes due 2036 (the “Notes”) pursuant to this Twenty-Fourth Supplemental Indenture have been authorized by resolutions adopted by the Board of Directors of the Company;
Supporting evidence: WHEREAS, the issuance and sale of $500,000,000 aggregate principal amount of a new series of the Company’s 5.000% Senior Notes due 2036 (the “Notes”) pursuant to this Twenty-Fourth Supplemental Indenture have been authorized by resolutions adopted by the Board of Directors of the Company;
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
2.64×
Peer median 6.93×
EV/EBIT
18.72×
Peer median 34.53×
P/E (TTM)
24.52×
Peer median 35.17×
Peer medians compare against the 23 similar-size Diagnostics & Research companies (of 48 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
Component
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Diagnostic Information Services Business
$10,785,000,000
$9,614,000,000
$8,976,000,000
$9,609,000,000
$10,494,000,000
$9,139,000,000
$7,405,000,000
$7,204,000,000
All Other Segments
$250,000,000
$258,000,000
$276,000,000
$274,000,000
$294,000,000
$298,000,000
$321,000,000
$327,000,000
By Product & Service (USD)
Component
FY2021
FY2020
FY2019
FY2018
FY2017
Routine Clinical Testing Services
$4,293,000,000
$3,836,000,000
$4,206,000,000
$4,217,000,000
$4,006,000,000
Genebased And Esoteric Testing Services
$2,878,000,000
$2,098,000,000
$2,620,000,000
$2,409,000,000
$2,449,000,000
COVID19 Testing Services
$2,770,000,000
$2,723,000,000
$0
$0
—
Anatomic Pathology Testing Services
$553,000,000
$482,000,000
$579,000,000
$578,000,000
$612,000,000
All Other Services
$294,000,000
$298,000,000
$321,000,000
$327,000,000
$335,000,000
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
